DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDABusiness Wire • 12/18/25
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business HighlightsBusiness Wire • 11/12/25
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in LondonBusiness Wire • 11/10/25
DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025Business Wire • 11/06/25
DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 09/17/25
After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is BrightZacks Investment Research • 09/09/25
Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to TradeZacks Investment Research • 09/08/25
What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 08/28/25
Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect?Zacks Investment Research • 08/19/25
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business HighlightsBusiness Wire • 08/12/25
DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025Business Wire • 08/05/25
DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction PipelineBusiness Wire • 07/21/25
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental TransferBusiness Wire • 07/17/25
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® IndexesBusiness Wire • 06/24/25
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025Business Wire • 05/22/25
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of PreeclampsiaBusiness Wire • 05/19/25